A rapid reversed phase high performance liquid chromatographic method for determination of etoposide (VP-16) in human plasma. 2001

F H Shirazi, and G Bahrami, and D J Stewart, and E Tomiak, and F Delorme, and D Noel, and R Goel
Department of Toxicology and Pharmacology, Shaheed Beheshti Pharmacy School, PO Box 14155-6153, Tehran, Iran. fshirazi@ottawa.com

A rapid, simple and sensitive isocratic High Performance Liquid Chromatography (HPLC) method was developed to measure the concentration of etoposide in plasma samples with UV detection at 220 nm. The method uses a Bondapac C18 column at 60 degrees C. The mobile phase consists of Methanol: water (45:55 v/v) at a flow rate of 2.8 ml/min. Phenacetin was used as an internal standard. The plasma samples were extracted using ether with the organic layer evaporated under nitrogen. The residue was dissolved in 200 microl methanol with 20 microl injected into the HPLC column. The extraction method showed a recovery of 91.5+/-3% for etoposide. In this system, the retention time of phenacetin and etoposide were 3.3 and 4.4 min, respectively. The limit of detection of etoposide in plasma is 20 ng/ml and the limit of quantitation is 40 ng/ml. This analytical method has very good reproducibility (8.1% between-day variability at a concentration of 50 ng/ml). It is a fast, sensitive and economic method applicable for clinical and pharmacokinetic studies.

UI MeSH Term Description Entries
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D005047 Etoposide A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. Demethyl Epipodophyllotoxin Ethylidine Glucoside,Celltop,Eposide,Eposin,Eto-GRY,Etomedac,Etopos,Etoposide Pierre Fabre,Etoposide Teva,Etoposide, (5S)-Isomer,Etoposide, (5a alpha)-Isomer,Etoposide, (5a alpha,9 alpha)-Isomer,Etoposide, alpha-D-Glucopyranosyl Isomer,Etoposido Ferrer Farma,Exitop,Lastet,NSC-141540,Onkoposid,Riboposid,Toposar,VP 16-213,VP-16,Vepesid,Vépéside-Sandoz,Eto GRY,Etoposide, alpha D Glucopyranosyl Isomer,NSC 141540,NSC141540,Teva, Etoposide,VP 16,VP 16 213,VP 16213,VP16,Vépéside Sandoz,alpha-D-Glucopyranosyl Isomer Etoposide
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015203 Reproducibility of Results The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results. Reliability and Validity,Reliability of Result,Reproducibility Of Result,Reproducibility of Finding,Validity of Result,Validity of Results,Face Validity,Reliability (Epidemiology),Reliability of Results,Reproducibility of Findings,Test-Retest Reliability,Validity (Epidemiology),Finding Reproducibilities,Finding Reproducibility,Of Result, Reproducibility,Of Results, Reproducibility,Reliabilities, Test-Retest,Reliability, Test-Retest,Result Reliabilities,Result Reliability,Result Validities,Result Validity,Result, Reproducibility Of,Results, Reproducibility Of,Test Retest Reliability,Validity and Reliability,Validity, Face

Related Publications

F H Shirazi, and G Bahrami, and D J Stewart, and E Tomiak, and F Delorme, and D Noel, and R Goel
July 1997, Se pu = Chinese journal of chromatography,
F H Shirazi, and G Bahrami, and D J Stewart, and E Tomiak, and F Delorme, and D Noel, and R Goel
January 1980, Chemical & pharmaceutical bulletin,
F H Shirazi, and G Bahrami, and D J Stewart, and E Tomiak, and F Delorme, and D Noel, and R Goel
January 1985, Therapeutic drug monitoring,
F H Shirazi, and G Bahrami, and D J Stewart, and E Tomiak, and F Delorme, and D Noel, and R Goel
January 2013, Iranian journal of pharmaceutical research : IJPR,
F H Shirazi, and G Bahrami, and D J Stewart, and E Tomiak, and F Delorme, and D Noel, and R Goel
July 1994, Journal of pharmaceutical and biomedical analysis,
F H Shirazi, and G Bahrami, and D J Stewart, and E Tomiak, and F Delorme, and D Noel, and R Goel
August 1989, Journal of chromatography,
F H Shirazi, and G Bahrami, and D J Stewart, and E Tomiak, and F Delorme, and D Noel, and R Goel
January 2001, Bollettino chimico farmaceutico,
F H Shirazi, and G Bahrami, and D J Stewart, and E Tomiak, and F Delorme, and D Noel, and R Goel
January 1988, Journal of pharmaceutical and biomedical analysis,
F H Shirazi, and G Bahrami, and D J Stewart, and E Tomiak, and F Delorme, and D Noel, and R Goel
September 1998, Journal of pharmaceutical and biomedical analysis,
F H Shirazi, and G Bahrami, and D J Stewart, and E Tomiak, and F Delorme, and D Noel, and R Goel
January 2006, Journal of AOAC International,
Copied contents to your clipboard!